Volume 102, Issue 6 pp. 1132-1139
ORIGINAL ARTICLE - BASIC SCIENCE

Mid-term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry

Claudia Fiorina MD

Corresponding Author

Claudia Fiorina MD

Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Correspondence Claudia Fiorina, MD, Cardiac Catheterization Laboratory and Cardiothoracic, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Sciences, and Public Health, University of Brescia, Piazzale Spedali Civili, Brescia 1–25123, Italy.

Email: [email protected]

Search for more papers by this author
Mauro Massussi MD

Mauro Massussi MD

Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Search for more papers by this author
Marco Ancona MD

Marco Ancona MD

Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy

Search for more papers by this author
Matteo Montorfano MD

Matteo Montorfano MD

Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy

Search for more papers by this author
Anna Sonia Petronio MD

Anna Sonia Petronio MD

Cardio Thoracic and Vascular Department, Cardiac Catheterization Laboratory, University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

Search for more papers by this author
Giuseppe Tarantini MD

Giuseppe Tarantini MD

Division of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy

Search for more papers by this author
Fausto Castriota MD

Fausto Castriota MD

Interventional Cardiology Unit, Maria Cecilia Hospital, GVM Care and Research, Maria Cecilia Hospita, Ravenna, Italy

Search for more papers by this author
Giuliano Chizzola MD

Giuliano Chizzola MD

Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Search for more papers by this author
Giuliano Costa MD

Giuliano Costa MD

Division of Cardiology, A.O.U. Policlinico “G. Rodolico—San Marco”, University of Catania, Catania, Italy

Search for more papers by this author
Corrado Tamburino MD

Corrado Tamburino MD

Division of Cardiology, A.O.U. Policlinico “G. Rodolico—San Marco”, University of Catania, Catania, Italy

Search for more papers by this author
Marianna Adamo MD

Marianna Adamo MD

Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy

Search for more papers by this author
First published: 05 September 2023
Citations: 3

Commentary: Expert Article Analysis for: Bi-cuspid TAVR; bye or buy!

Abstract

Background

Limited data are available on transcatheter heart valves (THVs) durability in bicuspid aortic valve (BAV) stenosis.

Aims

To evaluate evaluating 4-year clinical and echocardiographic outcomes of patients with BAV undergoing transcatheter aortic valve implantation (TAVI).

Methods

The bicuSpid TAvi duraBILITY (STABILITY) registry is an Italian multicentre registry including all consecutive patients with BAV and severe aortic stenosis (AS), treated by means of TAVI between January 2011 and December 2017. Outcomes of interest were all-cause death at 4-year, over time changes in echocardiographic measurements, and THV durability according to the valve aortic research consortium (VARC)-3 update definitions.

Results

Study population included 109 patients (50% females; mean age 78 ± 7.5 years) with a mean Society of Thoracic Surgeons Predicted Risk of Mortality score of 5.1 ± 4.3%. Median follow-up (FU) duration was 4.1 years [interquartile range: 2.8–5.1]. The overall cumulative incidence of all-cause death by Kaplan–Meier estimates at 4 years was 32%. Compared to baseline, a significant decrease in transprosthetic mean gradient was obtained after TAVI (54 ± 16 vs. 10 ± 5 mmHg; p < 0.001), whereas a significant increase was observed at 4-year (13 ± 6.4 mmHg, p = 0.03). Cumulative incidence of hemodynamic valve dysfunction (HVD) was 4%. Six patients met HVD criteria: three moderate and three severe HVD. All three cases of severe HVD were clinically relevant (bioprosthetic valve failure [BVF]) with two patients receiving a reintervention (TAVI in TAVI), and one patient experiencing a valve-related death due to endocarditis.

Conclusions

The STABILITY registry suggests that in patients with severe AS and BAV undergoing TAVI, postprocedural clinical benefits might last, over time, up to 4-year FU. The low rates of severe HVD and BVF may support the hypothesis of good THV durability also in BAV recipient.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.